Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

NCTNCT05767086 (opens ClinicalTrials.gov in a new tab)Other id30.01.2023-E.94828
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
297 participants (actual)
Sponsor
Bezmialem Vakif University · Other
Design
Randomized · Open label (no masking)
Countries
1 country

Turkey (Türkiye)

Start
15 Mar 2023
Primary completion
30 Sept 2024
Completion
30 Sept 2024
First posted
14 Mar 2023
Last update posted
15 Oct 2024
Conditions
Infertility

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202320242025
  1. N/A

    Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

    NCT05767086

    15 Mar 2023 to 30 Sept 2024

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The aim of study is to evaluate the results of three different protocols for prevention of premature ovulation in ovarian stimulation cycles. All patients that undergo IVF cycles are randomly divided into three groups. The first group is cetrorelix, the second group is medroxyprogesterone acetate and the third group is dydrogesterone.

Interventions

  • Gonadotropin releasing hormone antagonist (Cetrotide)Drug
  • Medroxyprogesterone Acetate (Tarlusal)Drug
  • DydrogesteroneDrug

Arms3

  • Experimental

    Gonadotropin-releasing hormone (GnRH) antagonist

    Cetrotide® (0.25 mg, MerckSerono Pharmaceuticals, Darmstadt, Germany)

  • Experimental

    Medroxyprogesterone acetate

    Tarlusal® (5 mg, Deva Pharma, Istanbul, Turkey)

  • Experimental

    Dydrogesterone

    Duphaston® (10mg, Abbott Laboratories, Chicago, Illinois, ABD)

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Rate of clinical pregnancy

    Time frame · 4-5 weeks after IVF

    Registry description

    fetal heartbeat by transvaginal ultrasound

Secondary outcomes(1)

  1. Rate of ongoing pregnancy

    Time frame · Months 3

    Registry description

    Ongoing pregnancy rates 3 months after IVF

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2019

9 results

Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.

Beguería et al. 2019Human reproduction (Oxford, England)cited by 80

PMID 30927417DOI 10.1093/humrep/dez034PUB-30927417

Full text at the publisher9 results
Publisher pageSee results (9)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 20 Years up to 38 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Women aged 20-38 years who applied to the infertility clinic * BMI\<25 kg/m2 * AMH\>1 ng/mL Exclusion Criteria: * Adenomyosis * Endometriosis * Untreated uterine pathology * Hormonal therapy in the last 3 months * Contraindication for ovulation stimulation * BMI\>25 kg/m2 * AMH\<1 ng/mL

PepBank is a research reference. Talk to a doctor before you use any peptide.